Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor

被引:115
作者
Aktas, Y
Andrieux, K [1 ]
Alonso, MJ
Calvo, P
Gürsoy, RN
Couvreur, P
Çapan, Y
机构
[1] Univ Paris Sud, Fac Pharm, CNRS, UMR 8612, F-92296 Chatenay Malabry, France
[2] Hacettepe Univ, Fac Pharm, Dept Pharmaceut Technol, TR-06100 Ankara, Turkey
[3] Univ Santiago de Compostela, Dept Pharmaceut Technol, Sch Pharm, Santiago De Compostela 15782, Spain
关键词
chitosan; nanoparticles; Z-DEVD-FMK; HPLC;
D O I
10.1016/j.ijpharm.2005.03.027
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this work was to develop a formulation for Z-DEVD-FMK, a peptide which is a caspase inhibitor and has been used in experimental animal studies for a decade. Peptide loaded chitosan nanoparticles were obtained by ionotropic gelation process and Z-DEVD-FMK was quantified by an HPLC method. The influence of the initial peptide concentration on the nanoparticle characteristics and release behavior was evaluated. The CS nanoparticles have a particle diameter (Z-average) ranging from approximately 313-412 nm and a positive zeta potential (20-28 mV). The formulation with the initial peptide concentration of 400 ng/ml provided the highest loading capacity (0.46%) and the highest extent of release (65% at 24 h) suggesting the possibility to achieve a therapeutic dose. According to the data obtained, this chitosan-based nanotechnology opens new and interesting perspectives for anticaspase activity. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:378 / 383
页数:6
相关论文
共 19 条
  • [1] The potential of chitosan in ocular drug delivery
    Alonso, MJ
    Sánchez, A
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2003, 55 (11) : 1451 - 1463
  • [2] Chitosan as a nasal delivery system: The effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers
    Aspden, TJ
    Mason, JDT
    Jones, NS
    Lowe, J
    Skaugrud, O
    Illum, L
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (04) : 509 - 513
  • [3] The blood-brain barrier: an overview - Structure, regulation, and clinical implications
    Ballabh, P
    Braun, A
    Nedergaard, M
    [J]. NEUROBIOLOGY OF DISEASE, 2004, 16 (01) : 1 - 13
  • [4] Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting
    Brigger, I
    Morizet, J
    Aubert, G
    Chacun, H
    Terrier-Lacombe, MJ
    Couvreur, P
    Vassal, G
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (03) : 928 - 936
  • [5] Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery
    Calvo, P
    Gouritin, B
    Chacun, H
    Desmaële, D
    D'Angelo, J
    Noel, JP
    Georgin, D
    Fattal, E
    Andreux, JP
    Couvreur, P
    [J]. PHARMACEUTICAL RESEARCH, 2001, 18 (08) : 1157 - 1166
  • [6] Calvo P, 1997, J APPL POLYM SCI, V63, P125, DOI 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO
  • [7] 2-4
  • [8] Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat
    Calvo, P
    Gouritin, B
    Villarroya, H
    Eclancher, F
    Giannavola, C
    Klein, C
    Andreux, JP
    Couvreur, P
    [J]. EUROPEAN JOURNAL OF NEUROSCIENCE, 2002, 15 (08) : 1317 - 1326
  • [9] Chen J, 1998, J NEUROSCI, V18, P4914
  • [10] Chitosan nanoparticles:: a new vehicle for the improvement of the delivery of drugs to the ocular surface.: Application to cyclosporin A
    De Campos, AM
    Sánchez, A
    Alonso, MJ
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 224 (1-2) : 159 - 168